EU/3/08/565

Table of contents

About

On 22 September 2008, orphan designation (EU/3/08/565) was granted by the European Commission to Drugrecure Aps, Denmark, for drotrecogin alfa (activated) for the treatment of acute respiratory distress syndrome.

The sponsorship was transferred to Savara ApS, Denmark  in September 2016. The sponsor’s address was updated in November 2019.

Key facts

Active substance
drotrecogin alfa (activated)
Disease / condition
Treatment of acute respiratory distress syndrome (ARDS)
Date of first decision
22/09/2008
Outcome
Positive
EU designation number
EU/3/08/565

Sponsor's contact details

Savara ApS
Slotsmarken 17, 1. Th
2970 Hoersholm
Hovedstaden
Denmark
Tel: +45 7930 1417
E-mail: info@savarapharma.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating